The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
 
Carissa Beaulieu
No Relationships to Disclose
 
Sunita Ghosh
No Relationships to Disclose
 
Camilla Tajzler
No Relationships to Disclose
 
McKayla Kirkpatrick
No Relationships to Disclose
 
Vincent Castonguay
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS; Eisai; GlaxoSmithKline Canada; Ipsen; Janssen; Merck; Pfizer
Research Funding - AstraZeneca Canada (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Merck (Inst); Pfizer (Inst)
 
Lori Wood
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - Pfizer/EMD Serono
 
Jeffrey Graham
Honoraria - Ipsen; Janssen Oncology; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca; EMD Serono; ipsen; Janssen Oncology; Merck
 
Denis Soulieres
Honoraria - Adlai Nortye; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Adlai Nortye; Eisai; Ipsen; Merck; Pfizer
Research Funding - Adlai Nortye (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Rahul K. Bansal
Honoraria - Knight Therapeutics; McKesson Canada Corporation; Merck Canada Inc.
Consulting or Advisory Role - Knight Therapeutics; McKesson Canada Corporation
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Antonio Finelli
Stock and Other Ownership Interests - Abbvie; Medtronic
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Merck; Tersera
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Janssen Oncology; Tersera
 
Simon Tanguay
Honoraria - Merck; Tersera
Consulting or Advisory Role - Merck; Tersera
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)
 
Bimal Bhindi
Honoraria - Bayer; Merck
Consulting or Advisory Role - Bayer; Ferring; Janssen; Verity Pharmaceuticals
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
 
Rodney H. Breau
Honoraria - Astellas Pharma; Eisai; Knight Therapeutics; Merck; Tersera; Tersera; Tolmar
Research Funding - Tolmar
 
Naveen S. Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; Ipsen; Janssen; Merck; Pfizer; Seagen; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada; Seagen
Research Funding - Ipsen
Travel, Accommodations, Expenses - Eisai; Ipsen; Johnson & Johnson/Janssen; Pfizer